L. Myasoutova

发表

Joint replacement as an effective method to improve the quality of life of patients with rheumatoid arthritis

S. Lapshina, I. Akhtyamov, L. Myasoutova, 2013 .

Comparison of the Effects of Rituximab, Tumor Necrosis Factor Alpha Inhibitors and Non-Steroidal Antiinflammatory Drugs on Ankylosing Spondylitis Clinical Activity and Sacroileitis Intensity on Magnetic Resonance Imaging

M. A. Afanasyeva, S. Lapshina, L. Myasoutova, 2013 .

Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.

Yeong-Wook Song, Sung-Hwan Park, L. Myasoutova, 2016, Rheumatology.

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

E. Lee, S. Shim, C. Suh, 2017, BioDrugs.

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

E. Lee, S. Shim, C. Suh, 2016, Annals of the rheumatic diseases.

Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1

V. Mazurov, J. Lenaerts, L. Myasoutova, 2013, Annals of the rheumatic diseases.

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis

S. Shim, C. Suh, J. Choe, 2017, BioDrugs.

Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis

S. Shim, C. Suh, J. Choe, 2017, BioDrugs.

THU0274 Double-blind, placebo-controlled, 28-week trial of efficacy and safety of infliximab plus naproxen vs naproxen alone in patients with early, active axial spondyloarthritis treated with a submaximal dose of NSAIDS: Preliminary results of INFAST part I

V. Mazurov, L. Myasoutova, J. Sieper, 2013 .

Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2

V. Mazurov, J. Lenaerts, L. Myasoutova, 2013, Annals of the rheumatic diseases.

EFFICIENCY OF TRAINING PROGRAMS AIMED AT ANKYLOSING SPONDYLITIS EARLY DETECTION FOR PRIMARY CARE DOCTORS IN KAZAN

S. Lapshina, L. Myasoutova, S. Erdes, 2016 .

AB0886 Comparative Characteristics of the Change in Bone Mineral Density in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

S. Lapshina, L. Myasoutova, D. Abdulganieva, 2015 .

FRI0407 Electrophysiological Cardiac Remodeling in Patients with Ankylosing Spondylitis

S. Lapshina, L. Myasoutova, D. Abdulganieva, 2016 .

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

E. Lee, S. Shim, C. Suh, 2017, BioDrugs.

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

E. Lee, S. Shim, C. Suh, 2017, BioDrugs.

Study of the efficacy, Safety and tolerability of the combined uSe of glucoSamine Sulfate («artrakam») and chondroitin Sulfate («artradol») in patientS with oSteoarthritiS of the knee

S. Lapshina, I. Akhtyamov, L. Myasoutova, 2016 .